Hydrochloric Acid

Hydrochloric Acid

SCHEMBL527146

Cl.[CaH2].[KH].[NaH]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11155816-B2 Oligonucleotide conjugates ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) 2021-10-26 US disclosed
US-20210238601-A1 Oligonucleotide Conjugates ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) 2021-08-05 US disclosed
CN-110459328-B Clinical monitoring equipment 浙江大学 2020-07-28 CN disclosed
EP-3406718-A1 OLIGONUCLEOTIDE CONJUGATES Roche Innovation Center Copenhagen A/S (DK) 2018-11-28 EP disclosed
US-10077443-B2 Oligonucleotide conjugates ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) 2018-09-18 US disclosed
US-20180251764-A1 Oligonucleotide Conjugates ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) 2018-09-06 US disclosed
EP-2920307-B1 ANTI APOB ANTISENSE CONJUGATE COMPOUNDS ROCHE INNOVATION CT COPENHAGEN AS (DK) 2018-05-02 EP disclosed
US-20160289677-A1 APOB Antisense Conjugate Compounds ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2016-10-06 US disclosed
EP-3068885-A1 APOB ANTISENSE CONJUGATE COMPOUNDS Roche Innovation Center Copenhagen A/S (DK) 2016-09-21 EP disclosed
US-20150368642-A1 LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2015-12-24 US disclosed
EP-2920307-A1 ANTI APOB ANTISENSE CONJUGATE COMPOUNDS Roche Innovation Center Copenhagen A/S (DK) 2015-09-23 EP disclosed
EP-2920304-A1 OLIGONUCLEOTIDE CONJUGATES Roche Innovation Center Copenhagen A/S (DK) 2015-09-23 EP disclosed
WO-2015071388-A1 APOB ANTISENSE CONJUGATE COMPOUNDS ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) 2015-05-21 WO disclosed
WO-2014118267-A1 LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES SANTARIS PHARMA A/S (DK) 2014-08-07 WO disclosed
WO-2014076196-A1 ANTI APOB ANTISENSE CONJUGATE COMPOUNDS SANTARIS PHARMA A/S (DK) 2014-05-22 WO disclosed
WO-2014076195-A1 OLIGONUCLEOTIDE CONJUGATES SANTARIS PHARMA A/S (DK) 2014-05-22 WO disclosed
WO-2012016229-A2 OXYTOCIN TREATMENT TO IMPROVE MEMORY AND MODIFY BLOOD GLUCOSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-02 WO disclosed
CN-101709083-B Fibrinolytic protein from scorpion tails, preparation method and application thereof GUANGDONG UNIVERSITY OF TECHNOLOGY (CN) 2012-02-01 CN disclosed
CN-101709083-A Fibrinolytic protein from scorpion tails, preparation method and application thereof UNIV GUANGDONG TECHNOLOGY 2010-05-19 CN disclosed
CN-101454017-A Method for elevating prolactin in mammals CARA THERAPEUTICS INC (US) 2009-06-10 CN disclosed